ARTICLE | Emerging Company Profile
Odyssey: Syndicate led by OrbiMed, SR One infuses Glick newco with $218M
Led by serial entrepreneur Gary Glick, a veteran team with a deep bench is building a pipeline in inflammation and oncology
December 7, 2021 12:03 PM UTC
As he built newly launched start-up Odyssey, serial entrepreneur Gary Glick followed a mantra from one of his mentors: “Hire as many people as you can who have made drugs before; they will know how to make drugs, and will make drugs again.”
That circa-2009 advice from Jeffrey Leiden, who would become chairman, president and CEO of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) three years later, has guided Glick through the creation of IFM Therapeutics Inc., Scorpion Therapeutics Inc., and now Odyssey Therapeutics Inc., which emerged from stealth Tuesday with $218 million in series A funding led by OrbiMed Advisors and co-led by SR One Capital Management...